Abstract
Nicotine cigarette smoke is a large public health burden worldwide, contributing to various types of disease. Anti-tobacco media campaigns and control programs have significantly reduced smoking in the United States, yet trends for menthol cigarette smoking have not been as promising. Menthol cigarette smoking is particularly prevalent among young adults and African Americans, with implications for long-term impacts on health care. Continuing high rates of menthol cigarette addiction call into question the role of menthol in nicotine addiction. To date, a biological basis for the high rate of addiction and relapse among menthol cigarette smokers has not been defined. Studies have demonstrated a role for menthol in the metabolism of nicotine in the body. More recent findings now reveal an interaction between menthol and the nicotinic acetylcholine (nACh) receptor in cells. This receptor is central to the actions of nicotine in the brain, and plays an important role in nicotine addiction. The newly discovered effect of menthol on nACh receptors may begin to explain the unique addictive properties of menthol cigarettes.
BEYOND FLAVOR: MENTHOL’S SUCCESS AS AN ADDITIVE TO CIGARETTES
Menthol is a monocyclic terpene alcohol used widely as a flavoring in various pharmaceutical and commercial products (; ). It is also a common additive to tobacco cigarettes. The isomer l-menthol, which has been used as an additive in cigarettes since 1926, is extracted from the peppermint plant Mentha arvensis. The concentration of menthol in cigarettes varies by brand but is present in 90% of all tobacco products (). It is used in menthol cigarettes to mask the harshness of smoke inhalation, increase the ease of smoking, and provide an oral sensation that appeals to many smokers. Today, menthol cigarettes account for 25% of the cigarette market in the United States (; ).
Targeted marketing strategies since the 1930’s have been effective in promoting smoking in young adults, women, and African Americans (; ; Figure 1). In the United States, the rate of menthol cigarette use has not receded even as the overall rate of smoking has declined in the general population. Young adults and teenagers in particular are more likely to try menthol cigarettes. Incidentally, young people who take up menthol cigarettes are 80% more likely to become life-long smokers than those who consume regular cigarettes (; ). These findings present an important question for public health regulators and scientists: are menthol cigarettes more addictive than other cigarettes? Negative findings with respect to the impact of mentholated cigarettes on cancer, smoking initiation and other health issues exist (; ; 1. In this article, I explore how recent findings on interactions between menthol and nicotinic acetylcholine (nACh) receptors can shed new light on the addictive potential of menthol cigarettes.
FIGURE 1
DOES MENTHOL CONTRIBUTE TO ADDICTION?
Traditionally, research into the addictive properties of tobacco cigarettes has focused on the actions of nicotine in the brain. The role of menthol has been attracting increasing attention, and emerging research suggests that menthol’s role in tobacco addiction deserves even closer scrutiny. One of the more significant scientific suggestions is that menthol can alter the metabolism of nicotine in the body. This effect of menthol is shown to provide smokers an enhanced exposure to systemic nicotine and its metabolites (
Menthol is known to directly activate the cold sensitive transient receptor potential melastatin (TRPM) ion channel in cells, which contributes to the cool nasal and oral sensation provided by menthol. Additionally, menthol has been shown to depress respiration and enhance nicotine’s presence in the lungs (
WAYS IN WHICH MENTHOL CAN CONTRIBUTE TO ADDICTION
MENTHOL ALTERS NICOTINE METABOLISM
A number of scientific studies show that menthol inhibits the metabolism of nicotine, thereby enhancing nicotine delivery via menthol cigarettes (
MENTHOL INTERACTS WITH THE NICOTINIC RECEPTOR
While nicotine is considered to mediate most of the pharmacological and addictive properties of tobacco via the actions of the nACh receptor in the brain (
Menthol directly regulates the actions of the nicotinic receptor in the cell
Prolonged cigarette smoking is associated with an increase in nACh receptor density throughout the brain (
Two other studies published this year by
Structural modeling based on sequence homology and docking simulations was also provided in
FIGURE 2

A role for menthol in modulating the activation of the α7 nACh receptor.(A) Nicotine is a known to bind and activate the α7 nACh receptor channel at the plasma membrane. Upon binding nicotine, the nACh receptor channel opens conducting calcium (and sodium) into the cell. (B) New findings by
Menthol alters the addictive properties of nicotine
Nicotinic receptors play a key role in addiction by regulating the release of several important neurotransmitters in the brain (
Strong preclinical evidence suggests that β2, α4, α5, α6, and α7 containing nAChRs mediate the reinforcing effects of nicotine (
For the α7 nACh receptor channel, which opens with a strong inward depolarizing calcium (and sodium) current in response to nicotine (
How menthol can engage the brain’s reward pathway is an important scientific question to consider. The role of menthol cigarettes in increasing the reinforcing effects of nicotine has been recently explored in rodents (
CONCLUSION
Recent findings on the ability of menthol to modulate nACh receptors suggest an important role for this compound in smoking addiction. While compelling, these studies are not yet conclusive. Rather, these findings point to the need for more studies to determine if and how menthol affects the activity of nACh receptors in the brain. Experiments using subunit specific nACh receptor knockout mice are a clear next step in the pharmacological and behavioral analysis of menthol function. Ex vivo studies in cultured cells and brain slices are also important to confirm and characterize interactions between menthol and the nACh receptor. For example, studies that examine menthol’s effects on nicotine self-administration in rodents will enable the assessment of dopamine (and glutamate release) in the brain following the administration of nicotine or nicotine with menthol. Subunit specific knockout mice for the α4,βb2,and α7 subunits as well as other nACh receptors (
Statements
Acknowledgments
This work is supported by a VYTP Grant Award on Research on the Causes and Prevention of Youth Tobacco to Nadine Kabbani.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
1.^The study was supported by tobacco industry funding.
2.^Liquid chromatography measures of free menthol in the brain of mice after a single intraperitoneal injection of menthol (100 mg/Kg), indicate 54.6 µg/g and 5 µg/g at 5 and 60 min after injection, respectively (Pan et al., 2012). Calculations based on an average adult mouse weight suggest that the levels of menthol in the brain are between 30 and 350 µM
REFERENCES
1
AboboC. V.MaJ.LiangD. (2012) Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation.Nicotine Tob. Res.14801–808. 10.1093/ntr/ntr287
2
AhijevychK.GarrettB. E. (2010) The role of menthol in cigarettes as a reinforcer of smoking behavior.Nicotine Tob. Res. 12(Suppl.2)S110–S116.10.1093/ntr/ntq203
3
AlbuquerqueE. X.PereiraE. F. R.AlkondonM.RogersS. W. (2009) Mammalian nicotinic acetylcholine receptors: from structure to function.Physiol. Rev.8973–120. 10.1152/physrev.00015.2008
4
AshoorA.NordmanJ. C.VeltriD.YangK. H. S.Al KuryL.ShubaY.et al (2013) Menthol binding and inhibition of α7-nicotinic acetylcholine receptors.PLoS ONE (in press).
5
BenowitzN. L. (2008) Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.Clin. Pharmacol. Ther.83531–541. 10.1038/clpt.2008.3
6
BenowitzN. L. (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.Annu. Rev. Pharmacol. Toxicol.4957–71. 10.1146/annurev.pharmtox.48.113006.094742
7
BenowitzN. L.DainsK. M.DempseyD.WilsonM.JacobP. (2011) Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.Nicotine Tob. Res.13772–783. 10.1093/ntr/ntr072
8
BerrettiniW. H.DoyleG. A. (2012) The CHRNA5-A3-B4 gene cluster in nicotine addiction.Mol. Psychiatry17856–866. 10.1038/mp.2011.122
9
BrodyA. L.MukhinA. G.La ChariteJ.TaK.FarahiJ.SugarC. A.et al (2013) Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers.Int. J. Neuropsychopharmacol.16957–966. 10.1017/S1461145712001022
10
BrunzellD. H.McIntoshJ. M. (2012) Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia.Neuropsychopharmacology371134–1143. 10.1038/npp.2011.299
11
ChangeuxJ.-P. (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice.Nat. Rev. Neurosci.11389–401. 10.1038/nrn2849
12
D’SilvaJ.BoyleR. G.LienR.RodeP.OkuyemiK. S. (2012) Cessation outcomes among treatment-seeking menthol and nonmenthol smokers.Am. J. Prev. Med. 43(Suppl.3)S242–S248. 10.1016/j.amepre.2012.07.033
13
DauphineeA. L.DoxeyJ. R.SchleicherN. C.FortmannS. P.HenriksenL. (2013) Racial differences in cigarette brand recognition and impact on youth smoking.BMC Public Health 13:170. 10.1186/1471-2458-13-170
14
EcclesR. (1994) Menthol and related cooling compounds.J. Pharm. Pharm.46618–630. 10.1111/j.2042-7158.1994.tb03871.x
15
FaganP.MoolchanE. T.HartA.RoseA.LawrenceD.ShaversV. L.et al (2010) Nicotine dependence and quitting behaviors among menthol and non-menthol smokers with similar consumptive patterns.Addiction105(Suppl.)55–74. 10.1111/j.1360-0443.2010.03190.x
16
FarcoJ. A.GrundmannO. (2013) Menthol – pharmacology of an important naturally medicinal “cool”.Mini Rev. Med. Chem.13124–131. 10.2174/138955713804484686
17
FriendK. (2002) Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns.Health Educ. Res.1785–98. 10.1093/her/17.1.85
18
GrabusS. D.MartinB. RImad DamajM. (2005) Nicotine physical dependence in the mouse: involvement of the alpha7 nicotinic receptor subtype.Eur. J. Pharmacol.51590–93. 10.1016/j.ejphar.2005.03.044
19
HansM.WilhelmM.SwandullaD. (2012) Menthol suppresses nicotinic acetylcholine receptor functioning in sensory neurons via allosteric modulation.Chem. Senses37463–469. 10.1093/chemse/bjr128
20
HeckJ. D. (2010) A review and assessment of menthol employed as a cigarette flavoring ingredient.Food Chem. Toxicol. 48(Suppl.2)S1–S38. 10.1016/j.fct.2009.11.002
21
HoffmanA. C. (2011) The health effects of menthol cigarettes as compared to non-menthol cigarettes.Tob. Induc. Dis. 9(Suppl.1)S7 10.1186/1617-9625-9-S1-S7
22
HoffmanA. C.MiceliD. (2011) Menthol cigarettes and smoking cessation behavior.Tob. Induc. Dis. 9(Suppl.1)S6 10.1186/1617-9625-9-S1-S6
23
HoffmanA. C.SimmonsD. (2011) Menthol cigarette smoking and nicotine dependence.Tob. Induc. Dis. 9(Suppl.1)S5 10.1186/1617-9625-9-S1-S5
24
JanssensA.VoetsT. (2011) Ligand stoichiometry of the cold- and menthol-activated channel TRPM8.J. Physiol. 589(Pt20)4827–4835. 10.1113/jphysiol.2011.216523
25
Le FollB.GoldbergS. R. (2009) Effects of nicotine in experimental animals and humans: an update on addictive properties.Handb. Exp. Pharmacol.192335–367. 10.1007/978-3-540-69248-5_12
26
MaskosU. (2008) The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology.Br. J. Pharmacol.153(SuppL.1)S438–S445. 10.1038/bjp.2008.5
27
MorettiM.MugnainiM.TessariM.ZoliM.GaimarriA.ManfrediI.et al (2010) A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes.Mol. Pharmacol.78287–296. 10.1124/mol.110.064071
28
OliverA. J.JensenJ. A.VogelR. I.AndersonA. J.HatsukamiD. K. (2013) Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects.Nicotine Tob. Res.1588–92. 10.1093/ntr/nts093
29
PanR.TianY.GaoR.LiH.ZhaoX.BarrettJ. E.et al (2012) Central mechanisms of menthol-induced analgesia.J. Pharmacol. Exp. Ther.343661–672. 10.1124/jpet.112.196717
30
PicciottoM. R.KennyP. J. (2013) Molecular mechanisms underlying behaviors related to nicotine addiction.Cold Spring Harb. Perspect. Med.3a012112 10.1101/cshperspect.a012112
31
RoseJ. E.BehmF. M. (2004) Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.Nicotine Tob. Res.6523–532. 10.1080/14622200410001696501
32
RosenbloomJ.ReesV. W.ReidK.WongJ.KinnunenT. (2012) A cross-sectional study on tobacco use and dependence among women: does menthol matter?Tob. Induc. Dis.1019 10.1186/1617-9625-10-19
33
StokerA. K.MarkouA. (2013) Unraveling the neurobiology of nicotine dependence using genetically engineered mice.Curr. Opin. Neurobiol.10.1016/j.conb.2013.02.013[Epub ahead of print].
34
UmezuT.MoritaM. (2003) Evidence for the involvement of dopamine in ambulation promoted by menthol in mice.J. Pharmacol. Sci.91125–135. 10.1254/jphs.91.125
35
WangJ.-C.KapoorM.GoateA. M. (2012) The genetics of substance dependence.Annu. Rev. Genomics Hum. Genet.13241–261. 10.1146/annurev-genom-090711-163844
36
WerleyM. S.CogginsC. R. E.LeeP. N. (2007) Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions.Regul. Toxicol. Pharmacol.47189–203. 10.1016/j.yrtph.2006.09.004
37
WilsonD. (2011) Advisory panel urges F. D. A to re-examine menthol in cigarettes.New York Times 19th July.
Summary
Keywords
menthol, addiction research, African Americans, nicotinic receptors, tobacco
Citation
Kabbani N (2013) Not so Cool? Menthol’s discovered actions on the nicotinic receptor and its implications for nicotine addiction. Front. Pharmacol. 4:95. doi: 10.3389/fphar.2013.00095
Received
29 May 2013
Accepted
08 July 2013
Published
23 July 2013
Volume
4 - 2013
Edited by
Jerrel Yakel, National Institute of Environmental Health Sciences, National Institutes of Health, USA
Reviewed by
David M. Lovinger, National Institutes of Health, USA; Alasdair Gibb, University College London, UK
Copyright
© Kabbani.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Nadine Kabbani, Department of Molecular Neuroscience, Krasnow Institute for Advanced Study, George Mason University, 4400 University Drive, Fairfax, VA 22030, USA e-mail: nkabbani@gmu.edu
This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Pharmacology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.